Exceptionally potent neutralization of middle east respiratory syndrome coronavirus by human monoclonal antibodies

Journal of Virology

Volumn 88, Issue 14, 2014, Pages 7796-7805

  Ying, Tianlei ^a   Du, Lanying ^b   Ju, Tina W ^a   Prabakaran, Ponraj ^a,c   Lau, Candy C Y ^d   Lu, Lu ^e   Liu, Qi ^e   Wang, Lili ^b   Feng, Yang ^a   Wang, Yanping ^a   Zheng, Bo Jian ^c   Yuen, Kwok Yung ^c   Jiang, Shibo ^b,e   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EPITOPE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY M336; MONOCLONAL ANTIBODY M337; MONOCLONAL ANTIBODY M338; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VITRONECTIN;

ANTIBODY AFFINITY; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; BINDING KINETICS; BINDING SITE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONAVIRUS INFECTION; DISSOCIATION CONSTANT; DRUG SCREENING; FRAGMENT ANTIGEN BINDING; HUMAN; HUMAN CELL; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MOLECULAR DOCKING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; RECEPTOR BINDING DOMAIN; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; BINDING SITES; CORONAVIRUS; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN G; KINETICS; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PROTEIN BINDING;

EID: 84904663317     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00912-14     Document Type: Article

References (32)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820. http://dx.doi.org/10.1056 /NEJMoa1211721.
2. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA. 2013. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369:407-416. http://dx.doi.org/10.1056/NEJMoa1306742.
3. Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, Al-Tawfiq JA, Alhakeem RF, Madani H, AlRabiah FA, Al Hajjar S, Al-Nassir, Albarrak WNA, Flemban H, Balkhy HH, Alsubaie S, Palser AL, Gall A, Bashford-Rogers R, Rambaut A, Zumla AI, Memish ZA. 2013. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 382:1993-2002. http://dx.doi.org/10.1016/S0140-6736(13)61887-5.
4. Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF, Preiser W. 2013. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg. Infect. Dis. 19:1697-1699. http://dx.doi.org/10.3201/eid1910.130946.
5. Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke GJ, Jonges M, Farag E, Diab A, Ghobashy H, Alhajri F, Al-Thani M, Al-Marri SA, Al Romaihi HE, Al Khal A, Bermingham A, Osterhaus AD, Alhajri MM, Koopmans MP. 2014. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 14:140-145. http://dx.doi.org/10.1016/S1473-3099(13)70690-X.
6. Graham RL, Donaldson EF, Baric RS. 2013. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11: 836-848. http://dx.doi.org/10.1038/nrmicro3143.
7. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. 2013. Treatment with interferonalpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19:1313-1317. http://dx.doi.org/10.1038/nm.3362.
8. Dimitrov DS. 2012. Therapeutic proteins. Methods Mol. Biol. 899:1-26. http://dx.doi.org/10.1007/978-1-61779-921-1_1.
9. Schrama D, Reisfeld RA, Becker JC. 2006. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5:147-159. http://dx.doi.org /10.1038/nrd1957.
10. Casadevall A, Dadachova E, Pirofski L. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695-703. http://dx.doi.org /10.1038/nrmicro974.
11. Carter PJ. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6:343-357. http://dx.doi.org/10.1038/nri1837.
12. Scott LJ, Lamb HM. 1999. Palivizumab. Drugs 58:305-313. http://dx.doi.org/10.2165/00003495-199958020-00009.
13. Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. 2009. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin. Biol. Ther. 9:355-368. http: //dx.doi.org/10.1517/14712590902763755.
14. Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 25:1421-1434. http: //dx.doi.org/10.1038/nbt1363.
15. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
16. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, Mungall BA, Feng YR, Choudhary A, Zhang MY, Feng Y, Wang LF, Xiao X, Eaton BT, Broder CC, Dimitrov DS. 2006. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80:891-899. http://dx.doi.org/10.1128/JVI.80.2.891-899.2006.
17. Bossart KN, Tachedjian M, McEachern JA, Crameri G, Zhu Z, Dimitrov DS, Broder CC, Wang LF. 2008. Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. Virology 372:357-371. http: //dx.doi.org/10.1016/j.virol.2007.11.011.
18. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 5:e1000642. http://dx.doi.org/10.1371 /journal.ppat.1000642.
19. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B. 2011. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci. Transl. Med. 3:105ra103.
20. Zhu ZY, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao XD, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128. http://dx.doi.org/10.1073/pnas.0701000104.
21. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, Jiang S. 2013. A truncated receptor-binding domain of MERSCoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587. http://dx.doi.org/10.1371 /journal.pone.0081587.
22. Marcatili P, Rosi A, Tramontano A. 2008. PIGS: automatic prediction of antibody structures. Bioinformatics 24:1953-1954. http://dx.doi.org/10.1093/bioinformatics/btn341.
23. Chen R, Li L, Weng Z. 2003. ZDOCK: an initial-stage protein-docking algorithm. Proteins 52:80-87. http://dx.doi.org/10.1002/prot.10389.
24. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF. 2013. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227-231. http://dx.doi.org/10.1038/nature12328.
25. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, Arledge KC, Chen YH, Zhang L, Wang X. 2013. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23:986-993. http://dx.doi.org/10.1038/cr.2013.92.
26. Devitt E. 2013. Lack of small animal model hinders MERS coronavirus research. Nat. Med. 19:952. http://dx.doi.org/10.1038/nm0813-952.
27. Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov DS. 2012. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front. Microbiol. 3:277. http: //dx.doi.org/10.3389/fmicb.2012.00277.
28. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. 2011. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J. Virol. 85:11048-11057. http://dx.doi.org/10.1128/JVI.05397-11.
29. Chan CH, Hadlock KG, Foung SK, Levy S. 2001. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97:1023-1026. http://dx.doi.org/10.1182/blood.V97.4.1023.
30. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS. 2013. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virol. Sin. 28:71-80. http://dx.doi.org/10.1007 /s12250-013-3313-x.
31. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S. 2013. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87:9939-9942. http://dx.doi.org/10.1128/JVI.01048-13.
32. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. 2013. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368:2487-2494. http://dx.doi.org/10.1056 /NEJMoa1303729.